4,5-Dimethyl-2-(4-methylphenyl)oxazole N-Oxide Hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4,5-Dimethyl-2-(4-methylphenyl)oxazole N-Oxide Hydrochloride
• 英文别名: 4,5-dimethyl-2-p-tolyl-oxazole-3-oxide hydrochloride；4,5-dimethyl-2-(4-methylphenyl)-3-oxido-1,3-oxazol-3-ium;hydrochloride
• 化学式: C₁₂H₁₃NO₂*ClH
• 分子量: 239.702
• InChiKey: UTGOXWRFDPYZIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.93
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,5-Dimethyl-2-(4-methylphenyl)oxazole N-Oxide Hydrochloride 在 甲基磺酰氯 作用下， 以 二氯甲烷 为溶剂， 以91%的产率得到4-(氯甲基)-5-甲基-2-(4-甲基苯)-1,3-恶唑
  参考文献：
  名称：

  WO2006/66694

  摘要：

  公开号：
• 作为产物：
  描述：

  对甲基苯甲醛 、 二乙酰一肟 在 盐酸 、 溶剂黄146 作用下， 反应 3.0h， 以91%的产率得到4,5-Dimethyl-2-(4-methylphenyl)oxazole N-Oxide Hydrochloride
  参考文献：
  名称：

  WO2006/66694

  摘要：

  公开号：

文献信息

• Hypoglycemic thiazolidinedione derivatives
  申请人：Pfizer Inc.

  公开号：US05036079A1

  公开（公告）日：1991-07-30

  Hypoglycemic thiazolidine-2,4-derivatives ##STR1## wherein the dotted line represents a bond or no bond; V is --CH.dbd.CH--, --N.dbd.CH--, --CH.dbd.N-- or S; W is CH.sub.2, CHOH, CO, C.dbd.NOR or --CH.dbd.CH--; X is S, O, NR.sup.1, --CH.dbd.N-- or --N.dbd.CH--; Y is CH or N; Z is hydrogen, (C.sub.1 -C.sub.7)alkyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, naphtyl, pyridyl, furyl, thienyl or phenyl mono- or disubstituted with the same or different groups which are (C.sub.1 -C.sub.3)alkyl, trifluoromethyl, (C.sub.1 -C.sub.3)alkoxy, fluoro, chloro or bromo; Z.sup.1 is hydrogen or (C.sub.1 -C.sub.3)alkyl; R is hydrogen or methyl; and n is 1, 2 or 3; a pharamceutically acceptable cationic salt thereof; or a pharmaceutically acceptable acid addition salt thereof when the compound contains basic nitrogen.

  低血糖噻唑烷-2,4-衍生物 ##STR1## 其中虚线表示键或无键；V是--CH.dbd.CH--, --N.dbd.CH--, --CH.dbd.N--或S；W是CH.sub.2，CHOH，CO，C.dbd.NOR或--CH.dbd.CH--；X是S，O，NR.sup.1，--CH.dbd.N--或--N.dbd.CH--；Y是CH或N；Z是氢，(C.sub.1-C.sub.7)烷基，(C.sub.3-C.sub.7)环烷基，苯基，萘基，吡啶基，呋喃基，噻吩基或苯基单取代或双取代，所述取代基为相同或不同的(C.sub.1-C.sub.3)烷基，三氟甲基，(C.sub.1-C.sub.3)烷氧基，氟，氯或溴；Z.sup.1是氢或(C.sub.1-C.sub.3)烷基；R是氢或甲基；n为1、2或3；其药学上可接受的阳离子盐；或当化合物含有碱性氮时，其药学上可接受的酸加成盐。
• METHOD FOR THE PREPARATION OF OXAZOLES BY CONDENSING AROMATIC ALDEHYDES WITH ALPHA-KETOXIMES TO FORM N-OXIDES AND REACTING SAME WITH ACTIVATIVED ACID DERIVATIVES
  申请人：HOLLA Wolfgang

  公开号：US20080058529A1

  公开（公告）日：2008-03-06

  The present invention is comprised of improved methods in the preparation of oxazoles which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.

  本发明涉及改进的制备噁唑的方法，其结果是产量更高，杂质和污染物更少。噁唑是合成药物活性物质的有价值的中间体，例如过氧化物酶体增殖物激活受体（PPAR）激动剂，这些药物活性物质可以对脂质和葡萄糖代谢产生积极影响。
• NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PREPARATION OF OXAZOLES AND PHARMACEUTICAL ACTIVES FOR THE REGULATION OF LIPID AND GLUCOSE METABOLISM
  申请人：HOLLA Wolfgang

  公开号：US20080114035A1

  公开（公告）日：2008-05-15

  The present invention is directed to compounds of Formula III wherein the R1-R7 groups or substituents are defined herein. The present invention also comprises improved methods in the preparation of oxazoles in which the compounds of Formula III are intermediates and which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.

  本发明涉及式III的化合物，其中R1-R7基团或取代基如本文所定义。本发明还包括改进的制备噁唑的方法，其中式III的化合物是中间体，并且可以获得更高的收率，同时减少杂质和污染物。噁唑是合成药物活性物质的有价值中间体，例如过氧化物酶体增殖物激活受体（PPAR）激动剂，这是一种药物活性物质，可以对脂质和葡萄糖代谢产生积极影响。
• METHOD FOR THE PRODUCTION OF OXAZOLES BY CONDENSING AROMATIC ALDEHYDES WITH a-KETOXIMES TO N-OXIDES AND THEN REACTING THE SAME WITH ACTIVATED ACID DERIVATIVES
  申请人：HOLLA Wolfgang

  公开号：US20090286988A1

  公开（公告）日：2009-11-19

  The invention is related to a process for preparing compounds of the formula IV by means of conversion of aromatic aldehydes of the formula I using α-ketoximes of the formula II via N-oxides of the formula III to halomethyloxazoles of the formula IV, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 , X 3 , o, n1 and n2 are as defined herein.

  本发明涉及一种制备式IV化合物的方法，该方法通过使用式I的芳香醛，使用式II的α-酮肟经过式III的N-氧化物转化为式IV的卤代甲氧噁唑。其中，R1、R2、R3、R4、R5、R6、R7、R8、X1、X2、X3、o、n1和n2的定义如本文所述。
• Method for the preparation of oxazoles by condensing aromatic aldehydes with α-ketoximes to form n-oxides and reacting same with activated acid derivatives
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US07544809B2

  公开（公告）日：2009-06-09

  The present invention is comprised of improved methods in the preparation of oxazoles which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.

  本发明涉及改进制备噁唑的方法，该方法可以获得更高的产量，同时减少杂质和污染物。噁唑是合成药物活性物质的有价值的中间体，例如过氧化物酶体增殖物激活受体（PPAR）激动剂，这些药物活性物质可以对脂质和葡萄糖代谢产生积极的影响。